Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II

Andreas Jungwirth, Andrew V Schally, Gabor Halmos, Kate Groot, Karoly Szepeshazi, Jacek Pinski, Patricia Armatis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BACKGROUND. Metastatic or recurrent renal cell carcinoma (RCC) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. No uniformly effective therapeutic agents are available for the management of patients with RCC. Hormones and growth factors may play a role in promoting the transformation and/or proliferation of kidney neoplasms. METHODS. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75), somatostatin analog RC-160, and bombesin antagonist RC-3940-II were tested for their effects on the growth of the Caki-I renal adenocarcinoma cell line xenografted into nude mice. RESULTS. After 4 weeks of treatment, tumor volume was significantly (P < 0.01) decreased in animals receiving RC- 160, to 167.5 ± 34.2 mm3, compared with the control group (485.7 ± 77.2 mm3). LH-RH antagonist SB-75 and bombesin antagonist RC-3940-II also significantly reduced the volume of Caki-I tumors, to 159.9 ± 18.1 and 234.7 ± 81.8 mm3, respectively. Somatostatin analog RC-160 decreased serum levels for growth hormone (GH) and insulin-like growth factor-I compared with controls. Treatment with RC-160, Cetrorelix, and RC-3940-II significantly reduced the number of high-affinity receptors for epidermal growth factor on Caki-I tumors. CONCLUSIONS. LH-RH antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II effectively inhibit the growth of human Caki-I renal adenocarcinomas in nude mice. These peptide analogs should be considered for the therapy of patients with metastatic or recurrent RCC.

Original languageEnglish
Pages (from-to)909-917
Number of pages9
JournalCancer
Volume82
Issue number5
DOIs
StatePublished - Mar 1 1998
Externally publishedYes

Fingerprint

Hormone Antagonists
Bombesin
Somatostatin
Renal Cell Carcinoma
Gonadotropin-Releasing Hormone
Growth
Nude Mice
Therapeutics
Kidney Neoplasms
Tumor Burden
Insulin-Like Growth Factor I
Growth Hormone
Neoplasms
Intercellular Signaling Peptides and Proteins
Radiotherapy
vapreotide
Hca(6)-Leu(13)-psi(CH2N)-Tac(14)-bombesin(6-14)
cetrorelix
Hormones
Drug Therapy

Keywords

  • Anticancer therapy
  • Bombesin antagonist
  • Luteinizing hormone-releasing hormone antagonist
  • Renal cell carcinoma
  • Somatostatin analog

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. / Jungwirth, Andreas; Schally, Andrew V; Halmos, Gabor; Groot, Kate; Szepeshazi, Karoly; Pinski, Jacek; Armatis, Patricia.

In: Cancer, Vol. 82, No. 5, 01.03.1998, p. 909-917.

Research output: Contribution to journalArticle

Jungwirth, Andreas ; Schally, Andrew V ; Halmos, Gabor ; Groot, Kate ; Szepeshazi, Karoly ; Pinski, Jacek ; Armatis, Patricia. / Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. In: Cancer. 1998 ; Vol. 82, No. 5. pp. 909-917.
@article{3566d0fc46c9460aa7e541e185d1475f,
title = "Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II",
abstract = "BACKGROUND. Metastatic or recurrent renal cell carcinoma (RCC) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. No uniformly effective therapeutic agents are available for the management of patients with RCC. Hormones and growth factors may play a role in promoting the transformation and/or proliferation of kidney neoplasms. METHODS. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75), somatostatin analog RC-160, and bombesin antagonist RC-3940-II were tested for their effects on the growth of the Caki-I renal adenocarcinoma cell line xenografted into nude mice. RESULTS. After 4 weeks of treatment, tumor volume was significantly (P < 0.01) decreased in animals receiving RC- 160, to 167.5 ± 34.2 mm3, compared with the control group (485.7 ± 77.2 mm3). LH-RH antagonist SB-75 and bombesin antagonist RC-3940-II also significantly reduced the volume of Caki-I tumors, to 159.9 ± 18.1 and 234.7 ± 81.8 mm3, respectively. Somatostatin analog RC-160 decreased serum levels for growth hormone (GH) and insulin-like growth factor-I compared with controls. Treatment with RC-160, Cetrorelix, and RC-3940-II significantly reduced the number of high-affinity receptors for epidermal growth factor on Caki-I tumors. CONCLUSIONS. LH-RH antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II effectively inhibit the growth of human Caki-I renal adenocarcinomas in nude mice. These peptide analogs should be considered for the therapy of patients with metastatic or recurrent RCC.",
keywords = "Anticancer therapy, Bombesin antagonist, Luteinizing hormone-releasing hormone antagonist, Renal cell carcinoma, Somatostatin analog",
author = "Andreas Jungwirth and Schally, {Andrew V} and Gabor Halmos and Kate Groot and Karoly Szepeshazi and Jacek Pinski and Patricia Armatis",
year = "1998",
month = "3",
day = "1",
doi = "10.1002/(SICI)1097-0142(19980301)82:5<909::AID-CNCR16>3.0.CO;2-4",
language = "English",
volume = "82",
pages = "909--917",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II

AU - Jungwirth, Andreas

AU - Schally, Andrew V

AU - Halmos, Gabor

AU - Groot, Kate

AU - Szepeshazi, Karoly

AU - Pinski, Jacek

AU - Armatis, Patricia

PY - 1998/3/1

Y1 - 1998/3/1

N2 - BACKGROUND. Metastatic or recurrent renal cell carcinoma (RCC) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. No uniformly effective therapeutic agents are available for the management of patients with RCC. Hormones and growth factors may play a role in promoting the transformation and/or proliferation of kidney neoplasms. METHODS. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75), somatostatin analog RC-160, and bombesin antagonist RC-3940-II were tested for their effects on the growth of the Caki-I renal adenocarcinoma cell line xenografted into nude mice. RESULTS. After 4 weeks of treatment, tumor volume was significantly (P < 0.01) decreased in animals receiving RC- 160, to 167.5 ± 34.2 mm3, compared with the control group (485.7 ± 77.2 mm3). LH-RH antagonist SB-75 and bombesin antagonist RC-3940-II also significantly reduced the volume of Caki-I tumors, to 159.9 ± 18.1 and 234.7 ± 81.8 mm3, respectively. Somatostatin analog RC-160 decreased serum levels for growth hormone (GH) and insulin-like growth factor-I compared with controls. Treatment with RC-160, Cetrorelix, and RC-3940-II significantly reduced the number of high-affinity receptors for epidermal growth factor on Caki-I tumors. CONCLUSIONS. LH-RH antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II effectively inhibit the growth of human Caki-I renal adenocarcinomas in nude mice. These peptide analogs should be considered for the therapy of patients with metastatic or recurrent RCC.

AB - BACKGROUND. Metastatic or recurrent renal cell carcinoma (RCC) is a therapeutic challenge because it is resistant to chemotherapy and external radiotherapy. No uniformly effective therapeutic agents are available for the management of patients with RCC. Hormones and growth factors may play a role in promoting the transformation and/or proliferation of kidney neoplasms. METHODS. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75), somatostatin analog RC-160, and bombesin antagonist RC-3940-II were tested for their effects on the growth of the Caki-I renal adenocarcinoma cell line xenografted into nude mice. RESULTS. After 4 weeks of treatment, tumor volume was significantly (P < 0.01) decreased in animals receiving RC- 160, to 167.5 ± 34.2 mm3, compared with the control group (485.7 ± 77.2 mm3). LH-RH antagonist SB-75 and bombesin antagonist RC-3940-II also significantly reduced the volume of Caki-I tumors, to 159.9 ± 18.1 and 234.7 ± 81.8 mm3, respectively. Somatostatin analog RC-160 decreased serum levels for growth hormone (GH) and insulin-like growth factor-I compared with controls. Treatment with RC-160, Cetrorelix, and RC-3940-II significantly reduced the number of high-affinity receptors for epidermal growth factor on Caki-I tumors. CONCLUSIONS. LH-RH antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II effectively inhibit the growth of human Caki-I renal adenocarcinomas in nude mice. These peptide analogs should be considered for the therapy of patients with metastatic or recurrent RCC.

KW - Anticancer therapy

KW - Bombesin antagonist

KW - Luteinizing hormone-releasing hormone antagonist

KW - Renal cell carcinoma

KW - Somatostatin analog

UR - http://www.scopus.com/inward/record.url?scp=0032032276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032032276&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980301)82:5<909::AID-CNCR16>3.0.CO;2-4

DO - 10.1002/(SICI)1097-0142(19980301)82:5<909::AID-CNCR16>3.0.CO;2-4

M3 - Article

VL - 82

SP - 909

EP - 917

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -